ACM
CLRB icon

Altium Capital Management’s Cellectar Biosciences CLRB Stock Holding History

Altium Capital Management’s Portfolio CLRB Stock Details CLRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-7,167
Closed -$64.3K – 36
2024
Q4 		$64.3K Hold
7,167
– – 0.02% 66
2024
Q3 		$460K Buy
+7,167
New +$473K 0.14% 57
2021
Q1 		– Sell
-2,840
Closed -$1.77M – 127
2020
Q4 		$1.77M Buy
+2,840
New +$1.31M 0.66% 71

Other funds holding CLRB

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SFA
Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return
BBA
Baader Bank Aktiengesellschaft Unterschleissheim, Germany $1.33B AUM 47.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Altium Capital Management's CLRB Position: Q1 2025 in Review

Altium Capital Management sold out of Cellectar Biosciences (CLRB) in Q1 2025, closing a stake of 7,167 shares — an estimated $64.3K sold.

Altium Capital Management first reported a position in CLRB in Q4 2020 and held it in 3 quarters. The position peaked at $1.77M in Q4 2020. 32 funds tracked by Wall St. Rank hold CLRB as of Q1 2025.

  • Altium Capital Management reported no remaining Cellectar Biosciences position as of Q1 2025 after selling out during the quarter.
  • Altium Capital Management sold 7,167 Cellectar Biosciences shares in Q1 2025, an estimated $64.3K.
  • Altium Capital Management first reported a position in Cellectar Biosciences in Q4 2020 and held it in 3 quarters.
  • Altium Capital Management's Cellectar Biosciences position peaked at $1.77M in Q4 2020.
  • 32 funds tracked by Wall St. Rank held Cellectar Biosciences as of Q1 2025.

Based on Altium Capital Management's 13F filing for Q1 2025, filed 9 May 2025.